Jiangsu Hengrui Pharmaceuticals (01276): The marketing authorization application for SHR-2004 injection has been accepted by the National Medical Products Administration.

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, Beijing Shengdi Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company"), received the "Notice of Acceptance" issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). The marketing authorization application for SHR-2004 injection, a Class 1 innovative drug of the Company and a coagulation factor XI (FXI) monoclonal antibody, has been accepted by the NMPA.